PARP blocker combos way to go in hotly contested market

28 June 2023

2020_pills_tablets_bottles_biotech_manufacturing_production_big

Research from industry analyst GlobalData suggests that Pfizer’s (NYSE: PFE) newly-approved PARP inhibitor-based combo could achieve sales of around $650 million by the end of the decade.

Pfizer recently received a green light from the US regulator to market Talzenna (talazoparib) plus Xtandi (enzalutamide) for certain people with metastatic castration-resistant prostate cancer (mCRPC).

Talzenna has long been available as an option in certain breast cancer indications, but the therapy has lagged behind market leader Lynparza (olaparib), from AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK